<DOC>
	<DOCNO>NCT02667444</DOCNO>
	<brief_summary>This 12 week , multi-center , double-blinded , randomize , vehicle-controlled , parallel group , study conduct approximately 1300 subject acne vulgaris US .</brief_summary>
	<brief_title>P3 Study Comparing Once Daily SB204 Vehicle Gel Acne</brief_title>
	<detailed_description>This double-blind , placebo control study subject moderate severe acne . Subjects satisfy entry criterion randomize SB204 4 % QD Vehicle Gel QD 1:1 ratio . Efficacy assessment include Investigator Global Assessments ( IGA ) inflammatory non-inflammatory lesion count . Subjects return post-Baseline evaluation Weeks 2 , 4 , 8 , 12/Early Termination ( ET ) .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Moderate severe acne Minimum 25 70 noninflammatory lesion ( open close comedo ) face Minimum 20 40 inflammatory lesion ( papule pustule ) Women childbearing potential pregnant , nursing , consider become pregnant Any dermatologic condition could interfere clinical evaluation include severe , recalcitrant cystic acne</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>